Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
68 hedge funds and large institutions have $350M invested in Mirati Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 15 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
15% less funds holding
Funds holding: 80 → 68 (-12)
30% less capital invested
Capital invested by funds: $499M → $350M (-$150M)
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$22.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$7.01M |
| 3 |
QF
QVT Financial
New York
|
+$6.88M |
| 4 |
PA
Perceptive Advisors
New York
|
+$6.1M |
| 5 |
VAM
Visium Asset Management
New York
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$28.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.22M |
| 3 |
Morgan Stanley
New York
|
-$2.09M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.15M |
| 5 |
SIM
Spark Investment Management
New York
|
-$1.03M |
MRTX Hedge Fund Activity: Q1 2016 in Review
68 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2016, worth a combined $350M — down 30% from $499M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MRTX and 3 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 33 added.
The largest buyer was Aviva Holdings, adding an estimated $22.9M. The largest seller was Boxer Capital, cutting an estimated $28.3M.
- 68 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2016, down from 80 in Q4 2015.
- Funds reported $350M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2016, down 30% quarter-over-quarter.
- 3 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2016 and 15 closed out, a net change of -12 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2016 was Aviva Holdings, an estimated $22.9M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2016 was Boxer Capital, an estimated $28.3M sold.
Based on aggregated 13F filings for Q1 2016.